182 related articles for article (PubMed ID: 29702023)
41. ¹⁸F-NaF PET/CT and ¹¹C-Choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization.
Koo PJ; David Crawford E
Oncology (Williston Park); 2014 Dec; 28(12):1057-62, 1064-5. PubMed ID: 25738199
[TBL] [Abstract][Full Text] [Related]
42. Therapy-induced bone changes in oncology imaging with
Ahmed N; Sadeq A; Marafi F; Gnanasegaran G; Usmani S
Ann Nucl Med; 2022 Apr; 36(4):329-339. PubMed ID: 35218508
[No Abstract] [Full Text] [Related]
43. Unsuspected Metastases to Muscles in Osteosarcoma Detected on 18F-Sodium Fluoride PET-CT.
Usmani S; Marafi F; Rasheed R; Bakiratharajan D; Al Maraghy M; Al Kandari F
Clin Nucl Med; 2018 Sep; 43(9):e343-e345. PubMed ID: 30080191
[TBL] [Abstract][Full Text] [Related]
44. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.
Hetzel M; Arslandemir C; König HH; Buck AK; Nüssle K; Glatting G; Gabelmann A; Hetzel J; Hombach V; Schirrmeister H
J Bone Miner Res; 2003 Dec; 18(12):2206-14. PubMed ID: 14672356
[TBL] [Abstract][Full Text] [Related]
45. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
46. Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer.
Ueda CE; Duarte PS; de Castroneves LA; Flávio J; Marin G; Sado HN; Sapienza MT; Hoff AO; Buchpiguel CA
Nucl Med Commun; 2020 May; 41(5):469-476. PubMed ID: 32187160
[TBL] [Abstract][Full Text] [Related]
47. Validation of the Semiautomatic Quantification of
Brito AE; Mourato F; Santos A; Mosci C; Ramos C; Etchebehere E
J Nucl Med Technol; 2018 Dec; 46(4):378-383. PubMed ID: 30076246
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
[TBL] [Abstract][Full Text] [Related]
49. Superiority of NaF PET/CT Over Chest CT in a Case of Osteosarcoma.
Morland D; Godard F; Lalire P; Eymard JC; Papathanassiou D
Clin Nucl Med; 2021 Jul; 46(7):584-585. PubMed ID: 33782283
[TBL] [Abstract][Full Text] [Related]
50. Rare Thyroid Cartilage Metastasis From Breast Cancer Visualized on 18F-NaF PET/CT.
Usmani S; Ahmed N; Ilyas MW; Murad S; Al Kandari F
Clin Nucl Med; 2021 Jan; 46(1):43-44. PubMed ID: 33156044
[TBL] [Abstract][Full Text] [Related]
51. Unusual Finding of a Tumor Thrombus Arising From Osteosarcoma Detected on 18F-NaF PET/CT.
Verma P; Purandare N; Agrawal A; Shah S; Rangarajan V
Clin Nucl Med; 2016 Jun; 41(6):e304-6. PubMed ID: 26909709
[TBL] [Abstract][Full Text] [Related]
52. 18F-Sodium Fluoride PET/CT in Paget Disease.
Cucchi F; Simonsen L; Abild-Nielsen AG; Broholm R
Clin Nucl Med; 2017 Jul; 42(7):553-554. PubMed ID: 28481796
[TBL] [Abstract][Full Text] [Related]
53. 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound.
Avery R; Kuo PH
Clin Nucl Med; 2013 Sep; 38(9):746-8. PubMed ID: 23797230
[TBL] [Abstract][Full Text] [Related]
54. Novel Musculoskeletal and Orthopedic Applications of
Raynor WY; Borja AJ; Hancin EC; Werner TJ; Alavi A; Revheim ME
PET Clin; 2021 Apr; 16(2):295-311. PubMed ID: 33589389
[TBL] [Abstract][Full Text] [Related]
55. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
56. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
Moragas M; Soler M; Riera E; García JR
Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of
Yellanki DP; Kothekar E; Al-Zaghal A; Cheng N; Werner TJ; Høilund-Carlsen PF; Alavi A
Hell J Nucl Med; 2018; 21(3):181-185. PubMed ID: 30411728
[TBL] [Abstract][Full Text] [Related]
58. A statistically optimized regional thresholding method (SORT) for bone lesion detection in
Perk T; Chen S; Harmon S; Lin C; Bradshaw T; Perlman S; Liu G; Jeraj R
Phys Med Biol; 2018 Nov; 63(22):225018. PubMed ID: 30457117
[TBL] [Abstract][Full Text] [Related]
59. Skeletal PET with 18F-fluoride: applying new technology to an old tracer.
Grant FD; Fahey FH; Packard AB; Davis RT; Alavi A; Treves ST
J Nucl Med; 2008 Jan; 49(1):68-78. PubMed ID: 18077529
[TBL] [Abstract][Full Text] [Related]
60. 18F-sodium fluoride PET/CT in oncology: an atlas of SUVs.
Sabbah N; Jackson T; Mosci C; Jamali M; Minamimoto R; Quon A; Mittra ES; Iagaru A
Clin Nucl Med; 2015 Apr; 40(4):e228-31. PubMed ID: 25546225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
